Massachusetts-based pharmaceutical company Biogen Idec has agreed to acquire UK based Convergence Pharmaceuticals (CP).
CP is a clinical-stage biopharmaceutical company and the acquisition is centered on a drug it is testing that is for treating a chronic pain disease called trigeminal neuralgia ,which consists of episodic, debilitating facial pain. CP would initially receive $200 million with an additional $475 million paid dependant on future milestones.
The acquisition is still subject to closing conditions from the UK and the US, including the waiting period required by the Hart-Scott-Rodino Antitrust Improvements Act from the US. The companies are not expecting any major difficulties and are hoping for the acquisition to clear within the first quarter of 2015.
Full Content: Post Online Media
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Justice Department Moves to End NCAA Transfer Rule
May 30, 2024 by
CPI
Kenya’s Competition Authority Proposes Tougher Regulations on Big Tech
May 30, 2024 by
CPI
KKR Secures EU Antitrust Approval for $24 Billion Acquisition of Telecom Italia’s Fixed-Line Network
May 30, 2024 by
CPI
European Court Sides with Tech Giants in Italian Regulatory Dispute
May 30, 2024 by
CPI
US Steel and Nippon Steel Secure International Approvals for $14.9B Merger
May 30, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Merger Guidelines Retrospective
May 21, 2024 by
CPI
Mergers of Complements
May 21, 2024 by
CPI
Personality Traits, Private Equity, and Merger Analysis
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Lessons in the Importance of Incipiency, Modern Economics, and Monopsony
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Sharpening Merger Analysis
May 21, 2024 by
CPI